Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
Despite good news about its lead drug, investors are rushing for the exits.
A wholly owned cancer drug could eventually reshape an important indication, and a new sickle-cell disease drug could be heading to the FDA as soon as next year.
GLYC earnings call for the period ending June 30, 2022.
GLYC earnings call for the period ending March 31, 2022.
GLYC earnings call for the period ending December 31, 2021.
GLYC earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.